We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




Glycoprotein-Specific Direct Platelet Autoantibody Testing in Immune Thrombocytopenia

By LabMedica International staff writers
Posted on 14 Jan 2020
Autoantibodies directed against platelet glycoproteins have long been accepted as a major pathophysiologic mechanism in immune thrombocytopenia (ITP), but platelet autoantibody (PA) testing has previously shown poor sensitivity for ITP diagnosis.

Direct assays for platelet autoantibodies, which measure antibodies on platelets, as opposed to indirect assays, which measure free antibodies in plasma, that are capable of detecting glycoprotein-specific autoantibodies are considered optimal for PA testing

Hematologists at the Massachusetts General Hospital (Boston, MA, USA) performed a comprehensive retrospective study of PA testing in adult patients with ITP strictly applying the criteria of the 2012 International Society on Thrombosis and Haemostasis (ISTH) and 2011 American Society of Hematology (ASH) guidelines. More...
Of 986 PA assays performed, 485 assays in 368 patients met criteria and were included.

All PA assays meeting inclusion criteria were performed by using the commercially available PakAuto assay (Immucor, Brookfield, WI, USA), a direct and indirect solid-phase enzyme-linked immunosorbent assay (ELISA)-based test measuring antibodies against GPIIb/IIIa, GPIb/IX, and GPIa/IIa. This direct glycoprotein-specific PA assay measures antibodies eluted from the surface of platelets. A result was positive if optical density values were equal to or greater than two times the value obtained for the mean of the negative controls for the corresponding glycoprotein.

The scientists reported that the sensitivity and specificity of a positive test result for diagnosis of active ITP (n = 228 patients) were 90% and 78%, respectively. Sensitivity and specificity of a negative test result for clinical remission (n = 61 assays) were 87% and 91%. Antibodies against both glycoprotein IIb (GPIIb)/IIIa and GPIb/IX were required for the presence of antibodies against GPIa/IIa in patients with ITP. Logistic regression analysis revealed that more positive autoantibodies predicted more severe disease (relative to nonsevere ITP, relative risk ratio for severe ITP and refractory ITP was 2.27 and 3.09, respectively. Sixty-four patients with ITP had multiple PA assays performed longitudinally: all 10 patients achieving remission converted from positive to negative serologic results, and evidence for epitope spreading was observed in 35% of patients with ongoing active disease.

The authors concluded that glycoprotein-specific direct PA testing performed using ISTH recommendations in patients meeting ASH diagnostic criteria is sensitive and specific for ITP diagnosis and reliably confirms clinical remission. More glycoproteins targeted by autoantibodies predicts for more severe disease. The study was published on December 31, 2019 in the journal Blood Advances.

Related Links:
Massachusetts General Hospital
Immucor



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
New
Gel Cards
DG Gel Cards
New
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.